Barclays Has Just Reaffirmed $20 Target Price Per Share on Mallinckrodt (NYSE:MNK) stock, While They’ve Also Reiterated Their Underweight Rating

August 9, 2018 - By Victoria Pittman

Investors sentiment increased to 0.9 in Q1 2018. Its up 0.19, from 0.71 in 2017Q4. It improved, as 38 investors sold Mallinckrodt Public Limited Company shares while 85 reduced holdings. 47 funds opened positions while 64 raised stakes. 96.44 million shares or 6.30% more from 90.73 million shares in 2017Q4 were reported.

Advsrs Asset Management stated it has 9 shares. Carroll Fincl Associate has 0% invested in Mallinckrodt Public Limited Company (NYSE:MNK). Rhumbline Advisers reported 0.01% stake. 4,911 were reported by Ls Investment Lc. Preferred Limited Liability Corporation holds 0.01% of its portfolio in Mallinckrodt Public Limited Company (NYSE:MNK) for 1,770 shares. Acadian Asset Limited Company holds 0.01% of its portfolio in Mallinckrodt Public Limited Company (NYSE:MNK) for 86,017 shares. Cibc Mkts Incorporated holds 0% or 19,854 shares in its portfolio. Manchester Mngmt Lc has invested 0% in Mallinckrodt Public Limited Company (NYSE:MNK). 48 were reported by Hanson Mcclain Inc. Lsv Asset Management has 0.06% invested in Mallinckrodt Public Limited Company (NYSE:MNK) for 2.63M shares. Pnc Gru Incorporated reported 0% in Mallinckrodt Public Limited Company (NYSE:MNK). The North Carolina-based First Personal Serv has invested 0% in Mallinckrodt Public Limited Company (NYSE:MNK). Ny State Teachers Retirement Sys holds 0.01% of its portfolio in Mallinckrodt Public Limited Company (NYSE:MNK) for 190,501 shares. Virginia Retirement Et Al reported 12,100 shares. Deutsche Bank & Trust Ag owns 158,655 shares.

Since May 9, 2018, it had 1 insider buy, and 1 insider sale for $4.14 million activity. On Wednesday, May 9 Flynn James E sold $4.19M worth of Mallinckrodt Public Limited Company (NYSE:MNK) or 312,928 shares.

Mallinckrodt (NYSE:MNK) Rating Reaffirmed

Expert analysts at Barclays now has a $20 target price on Mallinckrodt (NYSE:MNK). Barclays and their recent target price means a potential downside of -33.69 % from the company’s last stock price. The rating has been shown in a research report on Wednesday, 8 August.

Mallinckrodt Public Limited Company (NYSE:MNK) Ratings Coverage

Among 12 analysts covering Mallinckrodt (NYSE:MNK), 2 have Buy rating, 1 Sell and 9 Hold. Therefore 17% are positive. Mallinckrodt has $42.0 highest and $14 lowest target. $25.17’s average target is -16.55% below currents $30.16 stock price. Mallinckrodt had 22 analyst reports since February 27, 2018 according to SRatingsIntel. The stock of Mallinckrodt Public Limited Company (NYSE:MNK) has “Market Perform” rating given on Wednesday, August 8 by Raymond James. The firm has “Hold” rating given on Wednesday, August 8 by Stifel Nicolaus. The firm has “Hold” rating given on Monday, April 23 by Leerink Swann. As per Thursday, April 26, the company rating was maintained by Mizuho. The stock has “Buy” rating by Cantor Fitzgerald on Tuesday, February 27. Barclays Capital maintained the stock with “Underweight” rating in Wednesday, August 8 report. Mizuho maintained Mallinckrodt Public Limited Company (NYSE:MNK) rating on Tuesday, February 27. Mizuho has “Hold” rating and $21.0 target. FBR Capital maintained the shares of MNK in report on Thursday, June 28 with “Neutral” rating. The stock of Mallinckrodt Public Limited Company (NYSE:MNK) earned “Hold” rating by Stifel Nicolaus on Thursday, April 12. The company was maintained on Monday, June 18 by Stifel Nicolaus.

The stock increased 2.83% or $0.83 during the last trading session, reaching $30.16. About 2.19M shares traded. Mallinckrodt Public Limited Company (NYSE:MNK) has declined 59.76% since August 9, 2017 and is downtrending. It has underperformed by 72.33% the S&P500.

Mallinckrodt public limited company develops, makes, markets, and distributes branded and generic specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. The company has market cap of $2.51 billion. The companyÂ’s Specialty Brands segment markets branded pharmaceutical products for autoimmune and rare diseases, including the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and hemostasis products, and central nervous system drugs. It has a 1.64 P/E ratio. This segment offers Acthar, an injectable drug for various indications, such as neurology, rheumatology, nephrology, and pulmonology; Ofirmev, an intravenous formulation of acetaminophen for pain management; Inomax for inhalation; Therakos, an immunotherapy treatment platform; and Exalgo, a form of hydromorphone.

More notable recent Mallinckrodt Public Limited Company (NYSE:MNK) news were published by: Benzinga.com which released: “Earnings Scheduled For August 7, 2018” on August 07, 2018, also Nasdaq.com with their article: “Mid-Day Market Update: Mallinckrodt Climbs After Q2 Beat; Gemphire Therapeutics Shares Plummet” published on August 07, 2018, Benzinga.com published: “Mallinckrodt Downgraded By Raymond James On Lack Of ‘Rational Valuation Framework'” on August 08, 2018. More interesting news about Mallinckrodt Public Limited Company (NYSE:MNK) were released by: Seekingalpha.com and their article: “Premarket analyst action – healthcare” published on August 08, 2018 as well as Benzinga.com‘s news article titled: “77 Biggest Movers From Yesterday” with publication date: August 08, 2018.

Mallinckrodt Public Limited Company (NYSE:MNK) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.